PharmaPoint: Chronic Heart Failure - US Drug Forecast and Market Analysis to 2022
London (PRWEB) October 23, 2013 -- PharmaPoint: Chronic Heart Failure - US Drug Forecast and Market Analysis to 2022
Summary
GlobalData has released its new Country report, “PharmaPoint: Chronic Heart Failure - US Drug Forecast and Market Analysis to 2022”. The chronic heart failure (CHF) market is a mature market that has been slowly overtaken by generic drugs, and more branded products are expected to lose market exclusivity during the next few years. GlobalData predicts that the major global barriers that will play a crucial role in narrowing the global growth of the CHF market over the forecast period include the sparsely populated CHF pipeline and an increasing number of generic competitors in a market that is already heavily laden with generic drugs.
The US is the largest CHF market due to its having the highest CHF population and high drug prices. Over the forecast period, the major driver for growth is predicted to be the launch of Novartis’ LCZ-696 in 2015 in the US.
Scope
-Overview of CHF, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
-Detailed information on the key drugs in the US including product description, safety and efficacy profiles as well as a SWOT analysis.
-Sales forecast for the top drugs in US from 2012 to 2022.
-Analysis of the impact of key events as well the drivers and restraints affecting the US CHF market.
Reasons to buy
-Understand and capitalize by identifying products that are most likely to ensure a robust return
-Stay ahead of the competition by understanding the changing competitive landscape for CHF
-Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
-Make more informed business decisions from insightful and in-depth analysis of drug performance
-Obtain sales forecast for drugs from 2012 to 2022 in the US.
Table of Contents
1 Table of Contents 5
1.1 List of Tables 8
1.2 List of Figures 9
2 Introduction 10
2.1 Catalyst 10
2.2 Upcoming Related Reports 11
3 Disease Overview 12
3.1 Etiology and Pathophysiology 12
3.1.1 Etiology 12
3.1.2 Pathophysiology 14
3.2 Prognosis 18
3.3 Quality of Life 18
3.4 Symptoms 19
4 Disease Management 21
4.1 Treatment Overview 22
4.1.1 Pharmacological Treatments 24
4.1.2 Mechanical Devices 29
4.2 US 30
4.2.1 Diagnosis and Referral Patterns 30
4.2.2 Clinical Practice 31
5 Competitive Assessment 33
5.1 Overview 33
5.2 Strategic Competitor Assessment 33
5.3 Drug Profiles 35
5.3.1 Angiotensin-Converting Enzyme (ACE) Inhibitors 35
5.3.2 Diuretics 37
5.3.3 Angiotensin Receptor Blockers 39
5.3.4 Beta Blockers 48
5.3.5 Mineralocorticoid Receptor Antagonists 54
5.3.6 Digoxin 56
6 Opportunity and Unmet Need 58
6.1 Overview 58
6.2 Lack of Therapies for HF-PEF Patients 59
6.3 Lack of Therapies for Patients with Renal Impairment 60
6.4 Diagnosis of Asymptomatic Left Ventricular Dysfunction 60
6.5 Treatment of Patients with Multiple Comorbidities 61
6.6 Increase in Survival of CHF Patients 61
6.7 Unmet Needs Gap Analysis 62
6.8 Opportunity: Treatment of Patients with HF-PEF 63
6.9 Opportunity: Therapies for Patients with Renal Impairment and Multiple Comorbidities 63
6.10 Opportunity: New Drugs that Show Increase in Survival of CHF Patients 63
7 Pipeline Assessment 64
7.1 Overview 64
7.2 Promising Drugs in Clinical Development 65
7.2.1 LCZ-696 66
8 Market Outlook 71
8.1 United States 71
8.1.1 Forecast 71
8.1.2 Key Events 74
8.1.3 Drivers and Barriers 74
9 Appendix 76
9.1 Bibliography 76
9.2 Abbreviations 82
9.3 Methodology 85
9.4 Forecasting Methodology 85
9.4.1 NYHA Class Segmentation of Total Prevalent CHF Population 85
9.4.2 Diagnosed CHF Population 86
9.4.3 Drug-Treated CHF Population 86
9.4.4 Patient Population Breakdown: HF-REF versus HF-PEF 86
9.4.5 Treatment of HF-REF versus HF-PEF 87
9.4.6 Drugs Included in Each Therapeutic Class 87
9.4.7 Launch and Patent Expiry Dates 87
9.4.8 General Pricing Assumptions 88
9.4.9 Drugs Assumptions 88
9.4.10 Generic Erosion 91
9.5 Physicians and Specialists Included in this Study 92
9.6 Survey of Prescribing Physicians 93
9.7 About the Authors 94
9.7.1 Author 94
9.7.2 Global Head of Healthcare 94
9.8 About GlobalData 95
9.9 Disclaimer 95
List of Tables
Table 1: Leading Causes of CHF 13
Table 2: Other Causes of CHF 13
Table 3: Compensatory Mechanisms in CHF 14
Table 4: Typical Symptoms of CHF 19
Table 5: NYHA Classification of HF Based on Symptoms and Physical Ability of Patients 20
Table 6: ACC/AHA Classification of HF Based on Disease Progression 21
Table 7: NYHA Classification of HF Based on Symptoms and Physical Activity of Patients 21
Table 8: Commonly Used Treatment Guidelines for CHF 23
Table 9: Most Prescribed Drugs for CHF by NYHA Class in the US, 2012 25
Table 10: Select Products Used for CHF Treatment in the US, 2012 35
Table 11: Product Profile – Diovan 42
Table 12: Diovan SWOT Analysis, 2012 44
Table 13: Product Profile – Atacand 46
Table 14: Atacand SWOT Analysis, 2012 47
Table 15: Product Profile – Carvedilol 51
Table 16: Carvedilol SWOT Analysis, 2012 53
Table 17: Overall Unmet Needs – Current Level of Attainment 58
Table 18: Clinical Unmet Needs – Gap Analysis, 2013 62
Table 19: CHF – Promising Late-Stage Pipeline, 2012 65
Table 20: Comparison of Therapeutic Classes in Development for CHF, 2012 65
Table 21: Product Profile – LCZ-696 67
Table 22: LCZ-696 SWOT Analysis, 2012 70
Table 23: Sales Forecasts ($m) for CHF in the United States, 2012–2022 72
Table 24: Key Events Impacting Sales for CHF in the United States, 2012–2022 74
Table 25: CHF Market in the United States – Drivers and Barriers, 2012–2022 74
Table 26: Key Launch or Approval Dates 87
Table 27: Key Patent Expiries 88
Table 28: Physicians Surveyed, By Country 93
List of Figures
Figure 1: Worsening HF Leading to Chronic Disease 16
Figure 2: Drug-Treatment Rates of Patients Diagnosed with CHF in the US, by NYHA Class 24
Figure 3: Treatment of CHF Patients by Drug Class, US, 2012 32
Figure 4: Sales for CHF ($bn) in the United States, 2012–2022 73
Read the full report:
PharmaPoint: Chronic Heart Failure - US Drug Forecast and Market Analysis to 2022
For more information:
Sarah Smith
Research Advisor at Reportbuyer.com
Email: [email protected]
Tel: +44 208 816 85 48
Website: http://www.reportbuyer.com
Sarah Smith, Research Advisor at Reportbuyer.com, +44 208 816 85 48, [email protected]
Share this article